B+
Bull case
15%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
UNCY
Unicycive TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The CRL appears concentrated in third-party manufacturing rather than OLC clinical efficacy or safety, and no additional clinical data was requested [#IR-2026-06-30]. Cash of approximately $61.4 million provides time for remediation and a potential resubmission [#SEC-8K-2026-07-02].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -17.3.
What can break
Commercial launch, reimbursement, and dialysis-channel execution remain unproven.
Momentum
8
Value
41
Sentiment
65
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.50 · Bull $8.50 · Bear $2.75Analysis 2026-08-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $29.56
Why
Momentum8 · Δ7d +0.9
Value41 · Δ7d -0.1
Sentiment65 · Δ7d -17.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -17.3.
Contradictions & invalidation
- • Commercial launch, reimbursement, and dialysis-channel execution remain unproven.
- • Continued operating losses and potential future capital raises may dilute shareholders.
- • The same manufacturing deficiency has now produced repeat regulatory setbacks, the FDA inspection had not occurred during the review, and the approval timetable is unspecified [#IR-2026-06-30].
Catalyst clock
2026-06-30
FDA Complete Response Letter resets OLC approval timeline
Lead driver: Sentiment · See AI snapshot
Momentum
8
8% active weight
Current posture
7d trendFlat
Δ7d
+0.9
Δ21d
-3.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
65
45% active weight
Current posture
7d trendSoftening
Δ7d
-17.3
Δ21d
+0.0
Why this grade
Composite grade D. Momentum 7.8 / Value 40.6 / Sentiment 64.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-04. Scenario method
B
Base case
35%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Most likely
B-
Bear case
50%
Probability
Target price
$2.75
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$108.36M
Beta
1.85
Shares Out
27.86M
P/E (TTM) · Derived
-2.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.14
Rev YoY
-100.0%
EPS YoY
-87.8%
Gross Margin
+57.9%
Op Margin
-
Net Debt
-$41.07M
Current Ratio
3.81
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data